GlassScriptPhysician profile
Malcolm Irani
NPI 1285083618
$23,064.78
in general payments reported to CMS, 2019-2025
28 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.74 · 2021: $26.61 · 2022: $2,681 · 2023: $6,506 · 2024: $3,561 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,218 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,700 · Consulting Fee: $3,575 · Travel and Lodging: $1,629 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,218.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,700.00 |
| Consulting Fee | $3,575.00 |
| Travel and Lodging | $1,628.84 |
| Education | $218.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,929.64 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,734.01 | 2022-2023 | |
| Celgene Corporation | $1,257.50 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $984.80 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $966.39 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $845.83 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $751.89 | 2022-2025 | Tremfya, Remicade, Stelara |
| Lilly USA, LLC | $486.88 | 2022-2025 | Omvoh |
| Genzyme Corporation | $476.11 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $400.41 | 2022-2025 | Xifaxan, Trulance |
| Celltrion USA INC. | $228.64 | 2024-2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $205.85 | 2022-2025 | Rebyota |
| Ardelyx, INC. | $128.68 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $95.59 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $91.07 | 2025 | Zenpep |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $84.35 | 2021-2024 | Resolution 360 Clip |
| Phathom Pharmaceuticals, INC. | $58.96 | 2023-2024 | Voquezna |
| Merck Sharp & Dohme LLC | $57.88 | 2023-2024 | Dificid |
| Sandoz INC. | $48.59 | 2023-2024 | Hyrimoz |
| Pharmacosmos Therapeutics INC. | $47.92 | 2023 | Monoferric |
| Fresenius Kabi USA, LLC | $28.55 | 2023 | Idacio |
| Dynavax Technologies Corporation | $26.03 | 2025 | Heplisav-B |
| Madrigal Pharmaceuticals | $24.65 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $24.24 | 2025 | |
| Evoke Pharma, INC. | $23.54 | 2025 | |
| Ironwood Pharmaceuticals, INC | $22.57 | 2022 | |
| Braintree Laboratories, INC. | $17.47 | 2024 | Sutab, Suflave |
| Alfasigma USA, INC. | $16.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Irani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.